FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Delayed Deutsche Boerse AG 18:05:50 13/05/2024 BST | ||
| 1.27 EUR | -13.61% |
|
| Current month | +1.38% | ||
| 1 month | -13.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/05/24 | 1.27 | -13.61% | 0 |
| 10/05/24 | 1.47 | +0.68% | 0 |
| 09/05/24 | 1.46 | -5.19% | 0 |
| 08/05/24 | 1.54 | +3.36% | 0 |
| 07/05/24 | 1.49 | -12.35% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 13, 2024 at 06:05 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW2CPQ |
| ISIN | DE000SW2CPQ7 |
| Date issued | 17/08/2023 |
| Strike | 1,248 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.41 € |
|---|---|
| Lowest since issue | 1.21 € |
| Spread | 0.04 € |
| Spread % | 3.05% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
883.2
DKK
Average target price
908.7
DKK
Spread / Average Target
+2.88%
- Stock Market
- Certificates
- Certificat
